dapsone (PULM-001) / Pulmonem - LARVOL DELTA

Dapsone Coronavirus SARS-CoV-2 Trial (DAP-CORONA) COVID-19 (clinicaltrials.gov) - P3; N=3000; Recruiting; Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Dapsone Coronavirus SARS-CoV-2 Trial (DAP-CORONA) COVID-19 (clinicaltrials.gov) - P3; N=3000; Not yet recruiting; Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre; Trial completion date: Jan 2022 ➔ Jul 2022; Initiation date: Jul 2021 ➔ Oct 2021; Trial primary completion date: Dec 2021 ➔ Mar 2022

Clinical • Trial completion date • Trial initiation date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Dapsone Coronavirus SARS-CoV-2 Trial (DAP-CORONA) COVID-19 (clinicaltrials.gov) - P3; N=3000; Not yet recruiting; Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre

Clinical • New P3 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Phase III North American Clinical Trial for COVID-19 Treatment begins after FDA & Health Canada approval (GlobeNewswire) - "After months of preparation, a global phase III clinical trial sponsored by the Research Institute of the McGill University Health Centre (RI-MUHC), in partnership with Canadian start-up Pulmonem, begins an innovative treatment to reduce and possibly prevent the development of severe pulmonary inflammation caused by the COVID-19 virus. The clinical trial will test the use of PULM-001 in patients in the early stages of COVID-19. The is one of very few phase III clinical trials for COVID therapies to obtain approval from both the U.S. Food and Drug Administration (FDA) and Health Canada....The MUHC Foundation has already raised one million dollars needed to start the trial in Canada. Another $4 million is required to complete it in the United States and get cost-effective drugs to those in need."

Trial status • Infectious Disease • Novel Coronavirus Disease